Hormone Replacement Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

The Hormone Replacement Therapy Market is expected to advance at a substantial CAGR forecast till 2030 owing to the increasing burden of menopause, thyroid disorder, osteoporosis, male hypogonadism, along with the increasing research and development activities in hormone replacement therapy, among others across the globe.

The hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030. The hormone replacement therapy (HRT) market is experiencing significant growth, driven by the increasing prevalence of hormonal and targeted diseases like menopause and osteoporosis, along with an expanding geriatric population, which is driving the demand for hormone replacement therapy (HRT). Rising awareness about menopause management and interest in regenerative medicines, including anti-aging and reproductive cycle therapies, the surge in drug approvals, product launches, and the presence of key market players highlight the dynamic nature of the HRT market, which is projected to grow substantially from 2024 to 2030.

Hormone Replacement Therapy Market Dynamics:

One of the key aspect driving the hormone replacement therapy market is the rising awareness among women about the management of menopausal issues, across the globe.

The global average age for menopause onset in women is around 50 years. Women's estrogen and progesterone production levels decrease significantly after the age of 50. The pituitary gland compensates for the decrease in estrogen and progesterone production by increasing the production of follicle-stimulating hormone (FSH). This manifests physically in women as post-menopausal symptoms such as flushing and others. According to data published in 2022 by the World Health Organization (WHO), it was stated that, in 2021, women aged 50 and over accounted for 26% of all women and girls globally. The increasing burden of women aged 50 across the globe will ultimately increase the overall menopausal load, thereby increasing the demand for hormonal replacement therapy used in the management of menopausal issues such as flushing of the skin, perspiration, and palpitations, among others.

Additionally, the growing R&D activities by key players for the discovery of novel therapeutics to treat hormonal imbalances and rising product approvals are expected to aid in the growth of the studied market over the forecast period. The increasing contribution of key players in the expansion of novel therapies further drives the introduction of new products in the market. For instance, in January 2022, Ascendis Pharma A/S received European Commission's market authorization for its drug SKYTROFA for the treatment of children and adolescents suffering from growth hormone disorders. This product is the first once-weekly treatment for growth hormone deficiency in the pediatric population.

Also, in June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.

Therefore, the interplay of all the factors mentioned above collectively will drive the overall hormone replacement therapy market throughout the forecast period from 2024 to 2030.

However, the high cost of drug development, side effects associated with hormone replacement therapy, and the timeline of the stringent regulatory approval process may prove to be challenging factors for hormone replacement therapy market growth.

Hormone Replacement Therapy Market Segment Analysis:

Hormone Replacement Therapy Market by Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Hormone Replacement, and Others), Indication (Menopause, Hypothyroidism, Male Hypogonadism, Growth Hormone Deficiency, and Others), Route of Administration (Oral, Parenteral, and Transdermal), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the indication segment of the hormone replacement therapy market, the menopause category is expected to have a significant revenue share in 2023. This is primarily owing to the increasing prevalence of menopause in women across the globe, increasing product launches, strategic investments, and other activities by key players in this category which will aid in driving the market growth during the forecast period.

The rising number of women aged 50 and above will increase the overall burden of menopausal-related issues thereby increasing the demand for various HRT. For instance, combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT) is usually suggested for treating the symptoms of menopause during the menopausal transition. Thus, the increasing burden of women aged 50 and above will lead to an increase in the number of menopausal issues across the globe, ultimately leading to the increased demand for menopausal hormone replacement therapy.

Moreover, the presence of a robust number of menopausal issues treating hormonal replacement therapy in the pipeline will also drive market growth. For example, nearly 20 drugs are currently under clinical trial, which may create a profitable opportunity for the key players in the upcoming years.

Further, various other strategic steps by the key players in the market will help in increasing the demand for hormone replacement therapy. For instance, in June 2022, Astellas Pharma Inc. announced that a New Drug Application (NDA) for fezolinetant had been submitted to the U.S. Food and Drug Administration (FDA). Fezolinetant is an investigational oral, non-hormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.

Also, in September 2021, Theramex announced the approval of Bijuva/Bijuve across Europe and the UK. Bijuva, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in postmenopausal women with an intact uterus and at least 12 months since last menses, combines estradiol and progesterone in a single daily oral capsule.

Therefore, owing to all the above-mentioned factors, the demand for menopausal treating hormone replacement drugs is expected to surge, thereby the category is expected to witness considerable growth eventually contributing to the overall growth of the hormone replacement therapy market during the forecast period.

North America is expected to dominate the overall hormone replacement therapy market:

Among all the regions, North America is expected to dominate the hormone replacement therapy market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030.

This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, presence of key domicile players in the region, and others are the key factors that contribute to the growth of the hormone replacement therapy market in North America region during the forecast period from 2024 to 2030.

For instance, as per the recent data from a study conducted by the American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and around 20 million Americans have some form of thyroid disease annually. Also, as per the U.S. Department of Health and Human Services, it was reported that in 2022 nearly 43,800 new cases of thyroid cancer were diagnosed in the US. During thyroid cancer, physicians may prescribe thyroid hormone therapy to prevent the cancer cells from growing. Thus, the increasing prevalence of thyroid-related issues in the US will ultimately upsurge the demand for hormone replacement therapy in the region.

Further, major product launches, collaborative agreements between manufacturers, favorable reimbursement policies in the region, and others are factors responsible for the market growth in the region. For instance, in June 2023, Pfizer Inc. announced that DUAVEE® (conjugated estrogens/bazedoxifene), an estrogen-based menopause hormone therapy, was back in stock in the United States following a voluntary recall, relaunching it with improved packaging.

Therefore, the interplay of all the aforementioned factors would provide a conducive growth environment for the hormone replacement therapy market in the North American region.

Hormone Replacement Therapy Market key Players:

Some of the key market players operating in the hormone replacement therapy market include Abbott, Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

Recent Developmental Activities in the Hormone Replacement Therapy Market:

• In May 2023, Astellas Pharma Inc. announced the U.S. Food and Drug Administration (FDA) approval for VEOZAH (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
• In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labor and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorders. This product was the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
• In November 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China.

Key Takeaways from the Hormone Replacement Therapy Market Report Study

• Market size analysis for current hormone replacement therapy market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the hormone replacement therapy market.
• Various opportunities available for the other competitors in the hormone replacement therapy market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current hormone replacement therapy market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for hormone replacement therapy market growth in the coming future?

Target audience who can be benefited from this Hormone Replacement Therapy Market Report Study

• Hormone replacement therapy providers
• Research organizations and consulting companies
• Hormone replacement therapy related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in hormone replacement therapy
• Various end-users who want to know more about the hormone replacement therapy market and the latest developments in the hormone replacement therapy market.

Frequently Asked Questions for the Hormone Replacement Therapy Market:

1. What are hormone replacement therapy?

Hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body.

2. What is the market for hormone replacement therapy?

The hormone replacement therapy is estimated to grow at a CAGR of 6.48% during the forecast period from 2024 to 2030.

3. What are the drivers for the hormone replacement therapy market?

The hormone replacement therapy (HRT) market is experiencing significant growth, owing to the increasing prevalence of hormonal and targeted diseases like menopause and osteoporosis, along with an expanding geriatric population, which is driving the demand for hormone replacement therapy (HRT). Rising awareness about menopause management and interest in regenerative medicines, including anti-aging and reproductive cycle therapies, the surge in drug approvals, product launches, and the presence of key market players highlight the dynamic nature of the HRT market, which is projected to grow substantially from 2024 to 2030.

4. Who are the key players operating in the hormone replacement therapy market?

Some of the key market players operating in hormone replacement therapy market include Abbott., Novartis AG, Pfizer Inc., Merck KGaA, Bayer AG, Halozyme Therapeutics, Inc., Eli Lilly and Company, Viatris Inc., F.Hoffman-La Roche, Novo Nordisk A/S, Amgen Inc., Genentech, Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Ascendis Pharma Endocrinology, Inc., Vista Pharma, Inc., Clarus Therapeutics, Inc., Gedeon Richter Plc, Endo International plc, and others.

5. Which region has the highest share in the hormone replacement therapy market?

Among all the regions, North America is estimated to hold a significant revenue share in the hormone replacement therapy market. This can be ascribed to the increasing demand for hormone replacement drugs among women in the region owing to the increasing prevalence of menopausal-related issues. Further, the rising prevalence of growth deficiency disease, thyroid disorder, osteoporosis, hypogonadism, surging research and developmental activities in the region, presence of key domicile players in the region, and others are the key factors that contribute to the growth of the hormone replacement therapy market in North America region during the forecast period from 2024 to 2030.


This product will be delivered within 2 business days.